The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1189-1195

  Wang, Xiaofei ^a   Zhang, Yan ^a   Zhang, Xiwen ^a   Tian, Wenxia ^a   Feng, Wenli ^a   Chen, Tingmei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Curcumin analogue; Signal transducer and activator of transcription 3

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; HYDRAZINOCURCUMIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDRAZINES; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR;

EID: 84863381930     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1298     Document Type: Article

References (47)

1. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
2. Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as 'Curecumin': from kitchen to clinic. Biochem Pharmacol 75: 787-809, 2008.
3. Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
4. Shim JS, Kim DH, Jung HJ, et al: Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem 10: 2987-2992, 2002. (Pubitemid 34761878)
5. Rathore R, Jain JP, Srivastava A, et al: Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal 46: 374-380, 2008.
6. Kakudo Y, Shibata H, Otsuka K, Kato S and Ishioka C: Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 65: 2108-2114, 2005. (Pubitemid 40490116)
7. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
8. Heng MC: Curcumin targeted signaling pathways: basis for anti-photoaging and anti-carcinogenic therapy. Int J Dermatol 49: 608-622, 2010.
9. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004. (Pubitemid 38198738)
10. Alas S and Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9: 316-326, 2003. (Pubitemid 36109748)
11. Buettner R, Mora L and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002. (Pubitemid 35177340)
12. Shen Y, Devgan G, Darnell JJ and Bromberg J: Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 98: 1543-1548, 2001. (Pubitemid 32165535)
13. Real P, Sierra A, De Juan A, Segovia J, Lopez-Vega J and Fernandez-Luna J: Resistance to chemotherapy via Stat3- dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618, 2002. (Pubitemid 35398808)
14. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004. (Pubitemid 38524698)
15. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
16. Bharti A, Donato N and Aggarwal B: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171: 3863-3871, 2003. (Pubitemid 37254592)
17. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000. (Pubitemid 30339203)
18. Kaptein A, Paillard V and Saunders M: Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 271: 5961-5964, 1996. (Pubitemid 26095392)
19. Faruqi T, Gomez D, Bustelo X, Bar-Sagi D and Reich N: Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci USA 98: 9014-9019, 2001. (Pubitemid 32743861)
20. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2000. (Pubitemid 30339202)
21. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell 98: 295-303, 1999. (Pubitemid 29380565)
22. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999. (Pubitemid 29077388)
23. Epling-Burnette PK, Lui JH, Catlette-Falcone R, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001.
24. Alas S and Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137-5144, 2001. (Pubitemid 32681546)
25. Gritsko T, Williams A, Turkson J, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19, 2006. (Pubitemid 43166170)
26. Diaz N, Minton S, Cox C, et al: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12:20-28, 2006. (Pubitemid 43166171)
27. Bromberg JF: Activation of STAT proteins and growth control. Bioessays 23: 161-169, 2001.
28. Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749, 2002.
29. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 11: 595-596, 2005.
30. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 409-422, 2004.
31. Kim DJ, Chan KS, Sano S and Digiovanni J: Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 46: 725-731, 2007. (Pubitemid 47255194)
32. Xi S, Gooding WE and Grandis JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach:implications for cancer therapy. Oncogene 24: 970-979, 2005. (Pubitemid 40313874)
33. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002. (Pubitemid 34270888)
34. Xie TX, Huang FJ, Aldape KD, et al: Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res 66: 3188-3196, 2006.
35. Lin L, Hutzen B, Ball S, et al: New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci 100: 1719-1727, 2009.
36. Dechow TN, Pedranzini L, Leitch A, et al: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101: 10602-10607, 2004. (Pubitemid 38955788)
37. Xie TX, Wei D, Liu M, et al: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560, 2004. (Pubitemid 38658421)
38. Boise LH, Gonzalez-Garcia M, Postema CE, et al: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993. (Pubitemid 23259741)
39. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, et al: Bcl-xL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 120: 3033-3042, 1994.
40. Grad JM, Zeng XR and Boise LH: Regulation of Bcl-xL: a little bit to this and a little bit to STAT. Curr Opin Oncol 12: 543-549, 2001. (Pubitemid 32039653)
41. Zhou P, Qian L, Kozopas KM and Craig RW: Mcl-1, a bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89: 630-643, 1997. (Pubitemid 27051700)
42. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
43. Calo V, Migliavacca M, Bazan V, et al: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157-168, 2003. (Pubitemid 37485244)
44. Maofu FU, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004. (Pubitemid 39564581)
45. Spencer CA and Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56: 1-48, 1991.
46. Marcu KB, Bossone SA and Patel AJ: Myc function and regulation. Annu Rev Biochem 61: 809-860, 1992.
47. Facchini LM and Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 12: 633-651, 1998. (Pubitemid 28247143)